Cyclo Short Term Debt from 2010 to 2024

CYTHW Stock  USD 0.14  0.00  0.00%   
Cyclo Therapeutics Short Term Debt yearly trend continues to be fairly stable with very little volatility. Short Term Debt is likely to outpace its year average in 2024. During the period from 2010 to 2024, Cyclo Therapeutics Short Term Debt regression line of quarterly data had mean square error of 507.9 B and geometric mean of  155,152. View All Fundamentals
 
Short Term Debt  
First Reported
2000-09-30
Previous Quarter
M
Current Value
20.1 K
Quarterly Volatility
408.8 K
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cyclo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.3 K, Interest Expense of 181.7 K or Total Revenue of 995.2 K, as well as many indicators such as Price To Sales Ratio of 25.33, Dividend Yield of 0.0 or PTB Ratio of 7.66. Cyclo financial statements analysis is a perfect complement when working with Cyclo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cyclo Therapeutics Correlation against competitors.
For more information on how to buy Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Latest Cyclo Therapeutics' Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Cyclo Therapeutics over the last few years. It is Cyclo Therapeutics' Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Slightly volatile
   Short Term Debt   
       Timeline  

Cyclo Short Term Debt Regression Statistics

Arithmetic Mean609,640
Geometric Mean155,152
Coefficient Of Variation146.63
Mean Deviation704,896
Median131,512
Standard Deviation893,943
Sample Variance799.1B
Range2.4M
R-Value0.64
Mean Square Error507.9B
R-Squared0.41
Significance0.01
Slope127,967
Total Sum of Squares11.2T

Cyclo Short Term Debt History

20242.4 M
20232.3 M
2022M
2021153 K
2020131.5 K
201616.4 K
2015754 K

About Cyclo Therapeutics Financial Statements

Cyclo Therapeutics investors use historical fundamental indicators, such as Cyclo Therapeutics' Short Term Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cyclo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short Term Debt2.3 M2.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cyclo Stock Analysis

When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.